Last reviewed · How we verify
Brenetafusp and pembrolizumab
At a glance
| Generic name | Brenetafusp and pembrolizumab |
|---|---|
| Sponsor | Immunocore Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brenetafusp and pembrolizumab CI brief — competitive landscape report
- Brenetafusp and pembrolizumab updates RSS · CI watch RSS
- Immunocore Ltd portfolio CI